Option chain shows key data for ArriVent BioPharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ArriVent BioPharma.

ArriVent BioPharma (NASDAQ:AVBP) Stock, Option Chain

ARRIVENT BIOPHARMA INC

ArriVent BioPharma

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Future of Healthcare Access at Risk

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

General

AVBP

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib&#39;s potential in NSCLC. The analyst sees strong upside with a $37 price target.

ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside

Why It Matters

Markets

Trading Ideas

AMTM

CLDX

MSFT

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Recent Gains

Pre-Market Outlook

Movers

ACON

ALUR

ASST

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

ArriVent BioPharma Inc

Management

Press Releases

ArriVent Appoints Kristine Peterson to its Board of Directors

Earnings

ArriVent BioPharma Reports First Quarter 2024 Financial Results

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

Contracts

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

ArriVent BioPharma Reports Full Year 2024 Financial Results

Akebia Therapeutics

AnaptysBio

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Chimerix

Cogent Biosciences

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Kura Oncology

LENZ Therapeutics

MeiraGTx Hldgs

Organogenesis Holdings

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Replimune Group

Relay Therapeutics

Sage Therapeutics

Sionna Therapeutics

Valneva

Xencor

B. Riley Securities

Guggenheim

HC Wainwright & Co.

Citigroup

Oppenheimer

Comments

ArriVent BioPharma

ArriVent BioPharma (AVBP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga